Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To study the effect of mild and moderate hepatic impairment on the pharmacokinetics of
SAR302503.
Secondary Objective:
To assess the tolerability of SAR302503 given as a single dose up to 300 mg in subjects with
mild and moderate and hepatic impairment and in matched subjects with normal hepatic
function.